Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature
Author | dc.contributor.author | Mauras, Nelly | |
Author | dc.contributor.author | Ross, Judith L. | |
Author | dc.contributor.author | Gagliardi, Priscila | |
Author | dc.contributor.author | Yu, Y. Miles | |
Author | dc.contributor.author | Hossain, Jobayer | |
Author | dc.contributor.author | Permuy, Joseph | |
Author | dc.contributor.author | Damaso, Ligeia | |
Author | dc.contributor.author | Merinbaum, Debbie | |
Author | dc.contributor.author | Singh, Ravinder J. | |
Author | dc.contributor.author | Gaete, Ximena | |
Author | dc.contributor.author | Mericq, Verónica | |
Admission date | dc.date.accessioned | 2018-03-20T19:35:11Z | |
Available date | dc.date.available | 2018-03-20T19:35:11Z | |
Publication date | dc.date.issued | 2016-12 | |
Cita de ítem | dc.identifier.citation | J Clin Endocrinol Metab, December 2016, 101(12):4984 – 4993 | es_ES |
Identifier | dc.identifier.other | 10.1210/jc.2016-2891 | |
Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/146911 | |
Abstract | dc.description.abstract | Context: Growth of short children in puberty is limited by the effect of estrogen on epiphyseal fusion. Objectives: To compare: 1) the efficacy and safety of aromatase inhibitors (AIs) vs GH vs AI/GH on increasing adult height potential in pubertal boys with severe idiopathic short stature (ISS); and 2) differences in body composition among groups. Design: Randomized three-arm open-label comparator. Setting: Outpatient clinical research. Patients: Seventy-six pubertal boys [mean (SE) age, 14.1 (0.1) years] with ISS [height SD score (SDS), -2.3 (0.0)]. Intervention: Daily AIs (anastrozole or letrozole), GH, or AI/GH for 24-36 months. Outcomes: Anthropometry, bone ages, dual x-ray absorptiometry, spine x-rays, hormones, safety labs. Results: Height gain [mean (SE)] at 24 months was: AI, +14.0 (0.8) cm; GH, +17.1 (0.9) cm; AI/GH, + 18.9 (0.8) cm(P < .0006, analysis of covariance). Height SDS was: AI, -1.73 (0.12); GH, -1.43 (0.14); AI/GH, -1.25 (0.12) (P < .0012). Those treated through 36 months grew more. Regardless of treatment duration, height SDS at near-final height [n = 71; age, 17.4 (0.2) years; bone age, 15.3 (0.1) years; height achieved, similar to 97.6%] was: AI, -1.4 (0.1); GH, -1.4 (0.2); AI/GH, -1.0 (0.1) (P = .06). Absolute height change was: AI, +18.2 (1.6) cm; GH, +20.6 (1.5) cm; AI/GH, + 22.5 (1.4) cm (P = .01) (expected height gain at -2.0 height SDS, +13.0 cm). AI/GH had higher fat free mass accrual. Measures of bone health, safety labs, and adverse events were similar in all groups. Letrozole caused higher T and lower estradiol than anastrozole. Conclusions: Combination therapy with AI/GH increases height potential in pubertal boys with ISS more thanGHand AI alone treated for 24-36 months with a strong safety profile. | es_ES |
Patrocinador | dc.description.sponsorship | Thrasher Research Fund National Institutes of Health from the National Center for Advancing Translational Sciences UL1TR000135 | es_ES |
Lenguage | dc.language.iso | en | es_ES |
Publisher | dc.publisher | Endocrine Soc | es_ES |
Type of license | dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | * |
Link to License | dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | * |
Source | dc.source | Journal of Clinical Endocrinology & Metabolism | es_ES |
Título | dc.title | Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature | es_ES |
Document type | dc.type | Artículo de revista | |
Cataloguer | uchile.catalogador | pgv | es_ES |
Indexation | uchile.index | Artículo de publicación ISI | es_ES |
Files in this item
This item appears in the following Collection(s)
-
Artículos de revistas
Artículos de revistas